Skip to content

Effect of erythropoietin versus control group on the short-term prognosis in newborns with hypoxic- ischemic- encephalopathy

Effect of erythropoietin versus control group on the short-term prognosis in newborns with hypoxic- ischemic- encephalopathy: a randomized clinical trial

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20120215009014N334
Enrollment
64
Registered
2020-01-16
Start date
2020-02-04
Completion date
Unknown
Last updated
2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoxic ischemic encephalopathy. Hypoxic ischemic encephalopathy [HIE]

Interventions

Intervention 1: Intervention group: Routine treatment plus intravenous injection of erythropoietin 1000 U/kg/day on the first, second and third days and then every other day on the fifth, seventh, and

Sponsors

Hamedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Days to 28 Days

Inclusion criteria

Inclusion criteria: Newborn, Hypoxic- ischemic- encephalopathy

Exclusion criteria

Exclusion criteria: Congenital anomalies, Gestational age less than 36 weeks, Unperforated anus, Intracranial hemorrhage

Design outcomes

Primary

MeasureTime frame
Time to start oral nutrition. Timepoint: From the beginning of the intervention until two weeks thereafter. Method of measurement: By taking a history.;Seizure attacks. Timepoint: From the beginning of the intervention until two weeks thereafter. Method of measurement: With clinical examination.;Time of onset of consciousness. Timepoint: From the beginning of the intervention until two weeks thereafter. Method of measurement: With clinical examination.;Occurrence of death. Timepoint: From the beginning of the intervention until two weeks thereafter. Method of measurement: With clinical examination.;Duration of hospitalization. Timepoint: From the beginning of the intervention to two weeks thereafter. Method of measurement: Based on the medical document.

Secondary

MeasureTime frame
Drug complications such as induced topical hypothermia, bradycardia and subcutaneous necrosis. Timepoint: From the beginning of the intervention until two weeks later. Method of measurement: With clinical examination.;Drug complications such as thrombocytopenia. Timepoint: From the beginning of the intervention up to two weeks later. Method of measurement: By laboratory tests.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Tayebeh Ghalandari Navideh

Hamedan University of Medical Sciences

dr.ghalandari1@gmail.com+98 911 432 1196

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026